<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975945</url>
  </required_header>
  <id_info>
    <org_study_id>generalsurgery/2021/01</org_study_id>
    <nct_id>NCT04975945</nct_id>
  </id_info>
  <brief_title>Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI</brief_title>
  <official_title>A Randomized Controlled Study Assessing Prolonged Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration in Elective Clean and Clean-contaminated Surgeries for Prevention of Surgical Site Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Grant Medical College &amp; Sir J.J. Group of Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Grant Medical College &amp; Sir J.J. Group of Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to study the incidence of surgical site infection when patients&#xD;
      are given local versus parenteral antibiotics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing above 18 years of age, giving consent and undergoing open or laparoscopic&#xD;
      elective, CDC class I &amp; II surgeries will be recruited. Cases will be randomised into two&#xD;
      cohorts viz: parenteral antibiotic (Group A) vs single-time intra-operative intra-dermal&#xD;
      antibiotic administration group (Group B). In operation theatre, after induction of&#xD;
      anaesthesia, Group A will receive parenteral ceftriaxone (15-20mg/kg) whereas Group B will&#xD;
      receive single-time intra-operative intra-dermal ceftriaxone (15-20mg/kg diluted in 10 ml&#xD;
      normal saline). Post-operatively, incision site will be covered with occlusive dressing.&#xD;
      First check-dressing will be done after 48 hours as per the existing institutional practices.&#xD;
      After that surgical site will be inspected daily for wound infection. Patients with healthy&#xD;
      wound will be discharged at the discretion of the treating surgeon and will be asked to&#xD;
      follow up in General Surgery OPD weekly for one month. Cases who developed an SSI will have&#xD;
      samples collected from the afflicted area for bacterial culture and antibiotic susceptibility&#xD;
      testing. On development of SSI, the treating clinical team will commence antibiotic therapy&#xD;
      as per their protocols.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Surgical site infection</measure>
    <time_frame>1 month</time_frame>
    <description>Infection occurs within 30 days after the operation and infection involves only skin or subcutaneous tissue of the incision and at least one of the following:&#xD;
Purulent drainage, with or without laboratory confirmation, from the superficial incision.&#xD;
Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision.&#xD;
At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat and superficial incision is deliberately opened by surgeon, unless the incision is culture-negative.&#xD;
Diagnosis of superficial incisional SSI by the surgeon or attending physician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organism isolated from wound</measure>
    <time_frame>1 month</time_frame>
    <description>Microorganism grown on wound swab - Nominal data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total duration of hospital stay</measure>
    <time_frame>1 month</time_frame>
    <description>Number of days of stay in the hospital - Ratio data (Numerical)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Surgical Wound Infection</condition>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Local</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single-time intra-operative intra-dermal ceftriaxone (15-20mg/kg diluted in 10 ml normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parenteral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive parenteral ceftriaxone (15-20mg/kg) for prolonged duration as per local protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone Sodium</intervention_name>
    <description>Intravenous vs local action</description>
    <arm_group_label>Local</arm_group_label>
    <arm_group_label>Parenteral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients above the age of 18 years&#xD;
&#xD;
          -  Patients undergoing open and laparoscopic elective, CDC class I &amp; II surgeries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients exhibiting hypersensitivity reaction to ceftriaxone&#xD;
&#xD;
          -  Patients who are immunocompromised (retroviral disease and corticosteroid use)&#xD;
&#xD;
          -  Patients not consenting to be a part of this study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Febrile illness or leucocytosis at the time of surgery&#xD;
&#xD;
          -  Planned for staged/multiple interventions during the hospital stay (endoscopies,&#xD;
             image-guided biopsies etc)&#xD;
&#xD;
          -  Patients with a possible septic focus distant from the surgical site such as diabetic&#xD;
             foot ulcers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Parth B Gada</last_name>
    <phone>+919769888446</phone>
    <email>parthg1895@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Balamurugan Ganesan</last_name>
    <phone>+919688631691</phone>
    <email>balsmurugan@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grant Government Medical College and Sir JJ Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parth B Gada</last_name>
      <phone>09769888446</phone>
      <email>parthg1895@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Balamurugan Ganesan</last_name>
      <phone>+919688631691</phone>
      <email>balsmurugan@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rajeshwari Bhat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikhil Dhimole</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96.</citation>
    <PMID>10196487</PMID>
  </reference>
  <reference>
    <citation>Akhter MS, Verma R, Madhukar KP, Vaishampayan AR, Unadkat PC. Incidence of surgical site infection in postoperative patients at a tertiary care centre in India. J Wound Care. 2016 Apr;25(4):210-2, 214-7. doi: 10.12968/jowc.2016.25.4.210.</citation>
    <PMID>27064370</PMID>
  </reference>
  <reference>
    <citation>Kotisso B, Aseffa A. Surgical wound infection in a teaching hospital in Ethiopia. East Afr Med J. 1998 Jul;75(7):402-5.</citation>
    <PMID>9803631</PMID>
  </reference>
  <reference>
    <citation>Young PY, Khadaroo RG. Surgical site infections. Surg Clin North Am. 2014 Dec;94(6):1245-64. doi: 10.1016/j.suc.2014.08.008. Epub 2014 Oct 3. Review.</citation>
    <PMID>25440122</PMID>
  </reference>
  <reference>
    <citation>Holtz TH, Wenzel RP. Postdischarge surveillance for nosocomial wound infection: a brief review and commentary. Am J Infect Control. 1992 Aug;20(4):206-13. Review.</citation>
    <PMID>1524269</PMID>
  </reference>
  <reference>
    <citation>Patel IH, Kaplan SA. Pharmacokinetic profile of ceftriaxone in man. Am J Med. 1984 Oct 19;77(4C):17-25. Review.</citation>
    <PMID>6093513</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Grant Medical College &amp; Sir J.J. Group of Hospitals</investigator_affiliation>
    <investigator_full_name>Parth Bhavesh Gada</investigator_full_name>
    <investigator_title>Junior Resident</investigator_title>
  </responsible_party>
  <keyword>Ceftriaxone</keyword>
  <keyword>Surgical wound infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD will be available after contacting the PI on parthg1895@gmail.com</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Will be available on completion of the study</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

